Literature DB >> 11153256

Advances in the management of cervical cancer.

P G Rose1.   

Abstract

In the last decade a number of advances have occurred in the treatment of cervical cancer. These advances have resulted in a variety of benefits, including improved survival, improved quality of life and preservation of fertility in selected patients with early-stage disease. Because cervical cancer affects women earlier than does any other adult cancer, appropriate physician decisions can significantly affect longevity. This article reviews recent advances in the management of cervical cancer, including conservative surgery for microinvasive tumors, radical trachelectomy, adjuvant therapy for high-risk early-stage disease, use of chemotherapy as part of multimodality primary treatment and improvements in the management of recurrent disease. Recognition of these advances is important for the practicing obstetrician/gynecologist.

Entities:  

Mesh:

Year:  2000        PMID: 11153256

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  3 in total

1.  Perineural invasion in early-stage cervical cancer and its relevance following surgery.

Authors:  Yi Zhu; Guonan Zhang; Yan Yang; Ling Cui; Shijun Jia; Yu Shi; Shuiqin Song; Shiqiang Xu
Journal:  Oncol Lett       Date:  2018-02-26       Impact factor: 2.967

2.  Chemoradiotherapy is not superior to radiotherapy alone after radical surgery for cervical cancer patients with intermediate-risk factor.

Authors:  Hakyoung Kim; Won Park; Young Seok Kim; Yeon Joo Kim
Journal:  J Gynecol Oncol       Date:  2019-11-21       Impact factor: 4.401

3.  The trend and outcome of postsurgical therapy for high-risk early-stage cervical cancer with lymph node metastasis in Japan: a report from the Japan Society of Gynecologic Oncology (JSGO) guidelines evaluation committee.

Authors:  Masae Ikeda; Masako Shida; Shogo Shigeta; Satoru Nagase; Fumiaki Takahashi; Wataru Yamagami; Hidetaka Katabuchi; Nobuo Yaegashi; Daisuke Aoki; Mikio Mikami
Journal:  J Gynecol Oncol       Date:  2021-05       Impact factor: 4.401

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.